Cost-effectiveness of using a gene expression profiling test to aid in identifying the primary tumour in patients with cancer of unknown primary

M. B. Hannouf, E. Winquist, S. M. Mahmud, M. Brackstone, S. Sarma, G. Rodrigues, P. Rogan, Jeffrey S Hoch, G. S. Zaric

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We aimed to investigate the cost-effectiveness of a 2000-gene-expression profiling (GEP) test to help identify the primary tumor site when clinicopathological diagnostic evaluation was inconclusive in patients with cancer of unknown primary (CUP). We built a decision-analytic-model to project the lifetime clinical and economic consequences of different clinical management strategies for CUP. The model was parameterized using follow-up data from the Manitoba Cancer Registry, cost data from Manitoba Health administrative databases and secondary sources. The 2000-GEP-based strategy compared to current clinical practice resulted in an incremental cost-effectiveness ratio (ICER) of $44,151 per quality-adjusted life years (QALY) gained. The total annual-budget impact was $36.2 million per year. A value-of-information analysis revealed that the expected value of perfect information about the test's clinical impact was $4.2 million per year. The 2000-GEP test should be considered for adoption in CUP. Field evaluations of the test are associated with a large societal benefit.

Original languageEnglish (US)
Pages (from-to)286-300
Number of pages15
JournalPharmacogenomics Journal
Volume17
Issue number3
DOIs
StatePublished - Jun 1 2017
Externally publishedYes

Fingerprint

Gene Expression Profiling
Cost-Benefit Analysis
Manitoba
Neoplasms
Quality-Adjusted Life Years
Budgets
Registries
Economics
Databases
Costs and Cost Analysis
Health

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Cite this

Cost-effectiveness of using a gene expression profiling test to aid in identifying the primary tumour in patients with cancer of unknown primary. / Hannouf, M. B.; Winquist, E.; Mahmud, S. M.; Brackstone, M.; Sarma, S.; Rodrigues, G.; Rogan, P.; Hoch, Jeffrey S; Zaric, G. S.

In: Pharmacogenomics Journal, Vol. 17, No. 3, 01.06.2017, p. 286-300.

Research output: Contribution to journalArticle

Hannouf, M. B. ; Winquist, E. ; Mahmud, S. M. ; Brackstone, M. ; Sarma, S. ; Rodrigues, G. ; Rogan, P. ; Hoch, Jeffrey S ; Zaric, G. S. / Cost-effectiveness of using a gene expression profiling test to aid in identifying the primary tumour in patients with cancer of unknown primary. In: Pharmacogenomics Journal. 2017 ; Vol. 17, No. 3. pp. 286-300.
@article{faffb1fd7058444abe85bc9161b71289,
title = "Cost-effectiveness of using a gene expression profiling test to aid in identifying the primary tumour in patients with cancer of unknown primary",
abstract = "We aimed to investigate the cost-effectiveness of a 2000-gene-expression profiling (GEP) test to help identify the primary tumor site when clinicopathological diagnostic evaluation was inconclusive in patients with cancer of unknown primary (CUP). We built a decision-analytic-model to project the lifetime clinical and economic consequences of different clinical management strategies for CUP. The model was parameterized using follow-up data from the Manitoba Cancer Registry, cost data from Manitoba Health administrative databases and secondary sources. The 2000-GEP-based strategy compared to current clinical practice resulted in an incremental cost-effectiveness ratio (ICER) of $44,151 per quality-adjusted life years (QALY) gained. The total annual-budget impact was $36.2 million per year. A value-of-information analysis revealed that the expected value of perfect information about the test's clinical impact was $4.2 million per year. The 2000-GEP test should be considered for adoption in CUP. Field evaluations of the test are associated with a large societal benefit.",
author = "Hannouf, {M. B.} and E. Winquist and Mahmud, {S. M.} and M. Brackstone and S. Sarma and G. Rodrigues and P. Rogan and Hoch, {Jeffrey S} and Zaric, {G. S.}",
year = "2017",
month = "6",
day = "1",
doi = "10.1038/tpj.2015.94",
language = "English (US)",
volume = "17",
pages = "286--300",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Cost-effectiveness of using a gene expression profiling test to aid in identifying the primary tumour in patients with cancer of unknown primary

AU - Hannouf, M. B.

AU - Winquist, E.

AU - Mahmud, S. M.

AU - Brackstone, M.

AU - Sarma, S.

AU - Rodrigues, G.

AU - Rogan, P.

AU - Hoch, Jeffrey S

AU - Zaric, G. S.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - We aimed to investigate the cost-effectiveness of a 2000-gene-expression profiling (GEP) test to help identify the primary tumor site when clinicopathological diagnostic evaluation was inconclusive in patients with cancer of unknown primary (CUP). We built a decision-analytic-model to project the lifetime clinical and economic consequences of different clinical management strategies for CUP. The model was parameterized using follow-up data from the Manitoba Cancer Registry, cost data from Manitoba Health administrative databases and secondary sources. The 2000-GEP-based strategy compared to current clinical practice resulted in an incremental cost-effectiveness ratio (ICER) of $44,151 per quality-adjusted life years (QALY) gained. The total annual-budget impact was $36.2 million per year. A value-of-information analysis revealed that the expected value of perfect information about the test's clinical impact was $4.2 million per year. The 2000-GEP test should be considered for adoption in CUP. Field evaluations of the test are associated with a large societal benefit.

AB - We aimed to investigate the cost-effectiveness of a 2000-gene-expression profiling (GEP) test to help identify the primary tumor site when clinicopathological diagnostic evaluation was inconclusive in patients with cancer of unknown primary (CUP). We built a decision-analytic-model to project the lifetime clinical and economic consequences of different clinical management strategies for CUP. The model was parameterized using follow-up data from the Manitoba Cancer Registry, cost data from Manitoba Health administrative databases and secondary sources. The 2000-GEP-based strategy compared to current clinical practice resulted in an incremental cost-effectiveness ratio (ICER) of $44,151 per quality-adjusted life years (QALY) gained. The total annual-budget impact was $36.2 million per year. A value-of-information analysis revealed that the expected value of perfect information about the test's clinical impact was $4.2 million per year. The 2000-GEP test should be considered for adoption in CUP. Field evaluations of the test are associated with a large societal benefit.

UR - http://www.scopus.com/inward/record.url?scp=84961891730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961891730&partnerID=8YFLogxK

U2 - 10.1038/tpj.2015.94

DO - 10.1038/tpj.2015.94

M3 - Article

VL - 17

SP - 286

EP - 300

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 3

ER -